Online inquiry

IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15233MR)

This product GTTS-WQ15233MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15233MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5862MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ14895MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ13215MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ5172MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ2440MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ8703MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ15548MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ14345MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW